ResearcherNational Cancer Centre SingaporeActive in the last 2 years
Joycelyn Jie Xin Lee
Matched on ORCID iD 0000-0002-1070-6125; OpenAlex author ID A5069397149. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2021: 1 paper · 2022: none · 2023: 1 trial · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 4
- Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequent… Co-author DOI 10.1016/j.surg.2025.109872↗
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
- Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Contr… Co-author DOI 10.1245/s10434-024-16674-y↗
- Resected pancreatic adenocarcinoma: An Asian institution's experience. Co-author DOI 10.1002/cnr2.1393↗
Trials 1
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David Wai-Meng Tai · 4 shared papers, 2021–2026 · strength 0.82
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancrea… DOI 10.1016/j.esmoop.2025.105826↗
- Ye Xin Koh · 3 shared papers, 2021–2026 · strength 0.65
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Resected pancreatic adenocarcinoma: An Asian institution's experience. DOI 10.1002/cnr2.1393↗
- Kennedy Yao Yi Ng · 3 shared papers, 2021–2026 · strength 0.65
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Resected pancreatic adenocarcinoma: An Asian institution's experience. DOI 10.1002/cnr2.1393↗
- Brian K. P. Goh · 3 shared papers, 2021–2026 · strength 0.65
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Resected pancreatic adenocarcinoma: An Asian institution's experience. DOI 10.1002/cnr2.1393↗
- Hwee Leong Tan · 2 shared papers, 2025–2026 · strength 0.55
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Yun Zhao · 2 shared papers, 2025–2026 · strength 0.55
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Anna Ho Yin Chan · 1 shared paper, 2025 · strength 0.25
- Krittiya Korphaisarn · 1 shared paper, 2025 · strength 0.17
- Thierry Conroy · 1 shared paper, 2025 · strength 0.17
- Cosmas Rinaldi Adithya Lesmana · 1 shared paper, 2025 · strength 0.17
- Wen‐Chi Chou · 1 shared paper, 2025 · strength 0.17
- Myung Ah Lee · 1 shared paper, 2025 · strength 0.17
- Chunyi Hao · 1 shared paper, 2025 · strength 0.17
- Glenn Kunnath Bonney · 1 shared paper, 2025 · strength 0.17
- Akihiro Ohba · 1 shared paper, 2025 · strength 0.17
- Hei‐Cheul Jeung · 1 shared paper, 2025 · strength 0.17
- Li‐Tzong Chen · 1 shared paper, 2025 · strength 0.17
- Andrès M.R. Cervantes · 1 shared paper, 2025 · strength 0.17
- Makoto Ueno · 1 shared paper, 2025 · strength 0.17
- George E. Pentheroudakis · 1 shared paper, 2025 · strength 0.17
- Michel Pierre Ducreux · 1 shared paper, 2025 · strength 0.17
- Lei Wang · 1 shared paper, 2025 · strength 0.17
- Ser Yee Lee · 1 shared paper, 2021 · strength 0.10
- Pierce K. H. Chow · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.